CVAL.F Stock Overview
Engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Covalon Technologies Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.34 |
| 52 Week High | CA$3.08 |
| 52 Week Low | CA$0.73 |
| Beta | 0.64 |
| 1 Month Change | -16.43% |
| 3 Month Change | -3.70% |
| 1 Year Change | 207.94% |
| 3 Year Change | 13.62% |
| 5 Year Change | 49.04% |
| Change since IPO | 287.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| CVAL.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.4% | -5.6% | -3.5% |
| 1Y | 207.9% | -1.5% | 22.1% |
Return vs Industry: CVAL.F exceeded the US Biotechs industry which returned -1.5% over the past year.
Return vs Market: CVAL.F exceeded the US Market which returned 22.1% over the past year.
Price Volatility
| CVAL.F volatility | |
|---|---|
| CVAL.F Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CVAL.F has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CVAL.F's weekly volatility has decreased from 16% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Brent Ashton | www.covalon.com |
Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company’s platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity. It also offers medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device.
Covalon Technologies Ltd. Fundamentals Summary
| CVAL.F fundamental statistics | |
|---|---|
| Market cap | US$64.63m |
| Earnings (TTM) | -US$572.98k |
| Revenue (TTM) | US$20.32m |
3.2x
P/S Ratio-112.5x
P/E RatioIs CVAL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CVAL.F income statement (TTM) | |
|---|---|
| Revenue | CA$29.20m |
| Cost of Revenue | CA$12.71m |
| Gross Profit | CA$16.48m |
| Other Expenses | CA$17.30m |
| Earnings | -CA$823.40k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Jan 07, 2025
| Earnings per share (EPS) | -0.03 |
| Gross Margin | 56.45% |
| Net Profit Margin | -2.82% |
| Debt/Equity Ratio | 0% |
How did CVAL.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 01:15 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Covalon Technologies Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andre Uddin | Research Capital Corporation |